BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5751
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5701/ 49
- Ask / Lots0.5858/ 5
- Open / Previous Close0.0000 / 0.5751
- Day Range---
- 52 Week Range
- Volume3,130
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 8408 | 0.6 |
| 09:36 ET | 200 | 0.623 |
| 09:39 ET | 100 | 0.6115 |
| 09:41 ET | 13549 | 0.6115 |
| 09:43 ET | 12800 | 0.62 |
| 09:56 ET | 18770 | 0.59 |
| 09:57 ET | 847 | 0.59 |
| 10:01 ET | 250 | 0.5898 |
| 10:06 ET | 800 | 0.6 |
| 10:10 ET | 1200 | 0.6001 |
| 10:12 ET | 200 | 0.605 |
| 10:14 ET | 229 | 0.6001 |
| 10:19 ET | 950 | 0.615 |
| 10:24 ET | 815 | 0.6011 |
| 10:30 ET | 6865 | 0.5807 |
| 10:35 ET | 100 | 0.5803 |
| 10:37 ET | 500 | 0.585 |
| 10:39 ET | 600 | 0.5828 |
| 10:42 ET | 600 | 0.585 |
| 10:44 ET | 100 | 0.585 |
| 10:48 ET | 100 | 0.585 |
| 10:50 ET | 4248 | 0.587349 |
| 10:51 ET | 507 | 0.5897 |
| 10:53 ET | 700 | 0.58969 |
| 10:57 ET | 2501 | 0.5801 |
| 11:00 ET | 32841 | 0.58 |
| 11:02 ET | 100 | 0.5727 |
| 11:04 ET | 31109 | 0.571 |
| 11:06 ET | 900 | 0.5749 |
| 11:09 ET | 3642 | 0.575 |
| 11:11 ET | 400 | 0.573 |
| 11:18 ET | 7791 | 0.575 |
| 11:20 ET | 1000 | 0.575 |
| 11:26 ET | 14096 | 0.572 |
| 11:27 ET | 4500 | 0.573 |
| 11:29 ET | 8514 | 0.585 |
| 11:31 ET | 2331 | 0.582499 |
| 11:47 ET | 54122 | 0.58 |
| 12:05 ET | 1100 | 0.587 |
| 12:12 ET | 1255 | 0.594 |
| 12:14 ET | 400 | 0.58 |
| 12:27 ET | 195 | 0.587001 |
| 12:30 ET | 400 | 0.58 |
| 12:43 ET | 4000 | 0.58 |
| 12:48 ET | 1000 | 0.58 |
| 12:54 ET | 400 | 0.578 |
| 12:56 ET | 200 | 0.585 |
| 12:57 ET | 100 | 0.578 |
| 01:03 ET | 5500 | 0.578 |
| 01:08 ET | 3000 | 0.578 |
| 01:10 ET | 5371 | 0.582 |
| 01:12 ET | 100 | 0.5741 |
| 01:14 ET | 5000 | 0.585 |
| 01:19 ET | 400 | 0.574 |
| 01:35 ET | 1600 | 0.5849 |
| 01:46 ET | 600 | 0.575 |
| 01:53 ET | 2000 | 0.584799 |
| 01:55 ET | 2550 | 0.574 |
| 02:08 ET | 300 | 0.574 |
| 02:09 ET | 900 | 0.5779 |
| 02:18 ET | 400 | 0.571 |
| 02:20 ET | 10000 | 0.5848 |
| 02:29 ET | 3000 | 0.5848 |
| 02:31 ET | 400 | 0.573 |
| 02:36 ET | 7000 | 0.5847 |
| 02:40 ET | 8000 | 0.5848 |
| 02:45 ET | 400 | 0.573 |
| 02:47 ET | 400 | 0.571 |
| 02:51 ET | 100 | 0.5847 |
| 02:58 ET | 520 | 0.5847 |
| 03:05 ET | 400 | 0.571 |
| 03:14 ET | 2400 | 0.571 |
| 03:18 ET | 8870 | 0.579849 |
| 03:20 ET | 170 | 0.58 |
| 03:21 ET | 8620 | 0.58 |
| 03:25 ET | 212 | 0.58 |
| 03:27 ET | 788 | 0.58 |
| 03:32 ET | 200 | 0.575 |
| 03:34 ET | 200 | 0.575 |
| 03:39 ET | 3000 | 0.575 |
| 03:41 ET | 300 | 0.575 |
| 03:48 ET | 955 | 0.5751 |
| 03:50 ET | 300 | 0.5751 |
| 03:52 ET | 24470 | 0.5757 |
| 03:54 ET | 7858 | 0.575 |
| 03:56 ET | 4289 | 0.5751 |
| 03:57 ET | 3300 | 0.575153 |
| 03:59 ET | 1597 | 0.5751 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesPress Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 52.8M | -0.8x | --- |
Kronos Bio Inc | 56.8M | -0.5x | --- |
LAVA Therapeutics NV | 51.0M | -1.8x | --- |
Kezar Life Sciences Inc | 47.8M | -0.5x | --- |
Dyadic International Inc | 45.3M | -5.7x | --- |
Marker Therapeutics Inc | 41.4M | -3.4x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.8M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
